TSLP Antibody, Unconjugated, Rabbit, Polyclonal

Article Name:	TSLP Antibody, Unconjugated, Rabbit, Polyclonal
Biozol Catalog Number:	PRS-4021
Supplier Catalog Number:	4021
Alternative Catalog Number:	PRS-4021-0.02,PRS-4021-0.1
Manufacturer:	ProSci
Host:	Rabbit
Category:	Antikörper
Application:	ELISA, IHC-P, WB
Species Reactivity:	Human
Immunogen:	Anti-TSLP antibody (4021) was raised against a peptide corresponding to 17 amino acids near the carboxy terminus of human TSLP. The immunogen is located within the last 50 amino acids of TSLP.
Conjugation:	Unconjugated
Alternative Names:	TSLP Antibody: Thymic stromal lymphopoietin

Clonality:	Polyclonal
Concentration:	1 mg/mL
Molecular Weight:	Predicted: 18 kDObserved: 26 kD ( Post-modifications: 2 N-linked glycosylations).
NCBI:	85480
UniProt:	Q969D9
Buffer:	TSLP Antibody is supplied in PBS containing 0.02% sodium azide.
Form:	Liquid

Application Dilute:	Optimal dilutions for each application to be determined by the researcher.
Application Notes:	WB: 0.25 - 2 µg/mL, IHC-P: 2.5 µg/mL.Antibody validated: Western Blot in human samples, Immunohistochemistry and Immunocytochemistry in human samples. All other applications and species not yet tested.

	Figure 2 Western Blot Validation in Human Jurkat Cell LineLoading: 15 &956,g of lysates per lane.Antibodies: TSLP 4021 (A: 1 &956,g/mL, B: 2 &956,g/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
	Figure 3 Immunohistochemistry Validation of TSLP in Human Brain Tissue Immunohistochemical analysis of paraffin-embedded Human Brain Tissue using anti-TSLP antibody (4021) at 2.5 &956,g/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT, antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4&730,C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
	Figure 4 Induced Expression Validation in Human Oral Keratinocytes (Bjerkan et al., 2015) TSLP expression detected by anti-TSLP antibodies (4021) was upregulated in cultured human oral keratinocytes after 24 h in response to poly(I:C),
	Figure 6 Induced Expression Validation of TSLP in Human Corneal Epithelium (Lin et al., 2018) Immunohistochemical images showing theTSLP protein detected by anti-TSLP antibodies in donor corneal tissues without (Control) or after exposure to IL-32 ex vivo, an isotype IgG antibody was used as a negative control. The production of TSLP was increased after IL-32 treatment.
	Figure 7 Induced Expression Validation of TSLP in Human Corneal Tissues (Lin et al., 2013) Immunohistochemical images showing TSLP protein detected by anti-TSLP antibodies in ex vivo donor human corneal tissues without (B1) or with exposure to IL-33 (B2). An isotype IgG antibody (B3) was used as a negative control. Magnificaiton 400X. The staining confirms the increased level of TSLP after IL-33 treatment.
	Figure 8 Induced Expression Validation of TSLP in Mesenchymal Stromal Cells (MSCs). (Allakhverdi et al., 2013) Immunocytochemical images showing TSLP protein detected by anti-TSLP antibodies in BM-MSCs unstimulated (control) or stimulated with IL-1/TNF or supernatants of activated MCs (MCactSNT). Isotype is used as a negative control. The production of TSLP increased with the stimulated conditions.
	Figure 1 Western Blot Validation with Recombinant ProteinLoading: 30 ng of human TSLP recombinant protein per lane.Antibodies: TSLP 4021, 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.Lane 1: 0.25 &956,g/mLLane 2: 0.5 &956,g/mLLane 3: 1 &956,g/mL
	Figure 5 Regulated Expression Validation of TSLP in COPD Patients. (Anzalone et al., 2018) (A) shows NHBE cells, in the absence (Lane 2) or presence (Lane 3) of Tiotropium , were stimulated with rhIL-17A. (B) shows NHBE cells, with ISs from COPD patients untreated (Lane 2 and Lane 3) or treated (Lane 4) with anti-IL-17A antibody. (A) and (B) show TSLP expression decreases with the treatment of anti-cholinergic drugs.